ObjectiveTo discuss the effect of synthesized physical nursing care on the treatment of meibomian gland dysfunction (MGD) patients. MethodWe collected 100 MGD patients between March and September 2014, and randomized them into conventional and synthesized physical nursing care groups with 50 patients in each. We evaluated the subjective symptoms, the break-up time of tear-film and the function of lacrimal gland secretion before and after treatment. We surveyed the satisfaction of these patients during the follow-up. ResultsCompared with the conventional nursing care group, the synthesized group had less clinical symptoms, longer break-up times of tear-film and better lacrimal gland secretion function. The results showed remarkable statistical significance (P<0.05). ConclusionsSynthesized nursing care has significant effect on the treatment efficacy of MGD outpatients.
目的：探讨射频配合药物治疗疣状胃炎的疗效。方法:将胃镜诊断为疣状胃炎患者68例随机分为两组，射频配合药物治疗组用射频波25～40W对病灶行一次性“ 烧灼”，术后口服奥美拉唑胶囊4周；药物治疗组使用奥美拉唑治疗4周组作为对照组。两组若幽门螺杆菌(HP)阳性者均给予根除HP治疗。结果：射频配合药物治疗组症状缓解/消失率及疣状病灶消退率明显优于药物治疗组（P＜0.01）。结论：射频配合药物治疗疣状胃炎是一种较理想的、值得推广的有效方法，具有治疗彻底，操作技术简单,使用安全,病灶愈合快,治愈时间短,价格便宜,病人痛苦小等优点。
ObjectiveTo observe the clinical effect of Lacosamide (LCM) in the treatment of children with intractable epilepsy.Methods41 cases of refractory epilepsy patients who received LCM from March to July 2019 in department of Neurology, General Hospital of Henan Province were collected which included 21 males, 20 females, age were 4.6 ~ 15.5 years, average (7.21±3.06) years, And the efficacy of LCM was observed through blank control study.ResultsAfter LCM was added to the blank self-control group, the frequency of epileptic seizures was significantly reduced during the follow-up period of 3 months and 6 months, with statistically significant difference (P<0.05), and the mental state of the children was effectively improved, but there was no statistical significance between focal refractory epileptic seizure and comprehensive refractory epileptic seizure (P>0.05).ConclusionsLCM is a new kind of the third generation of antiepileptic drug. The addition use of LCM can effectively reduce the seizure frequency and improve mental state in children with refractory epilepsy.
【摘要】 目的 观察针刺法在治疗痔瘘术后疼痛的临床疗效。 方法 2009年1-6月，将符合纳入标准的93例痔瘘术后中度疼痛患者，随机分为治疗组49例与对照组44例。治疗组采用针刺治疗术后疼痛；对照组采用口服莫比可治疗术后疼痛，观察两组患者疼痛的消除程度。 结果 消除疼痛有效率治疗组为91.83%，对照组为68.18%，治疗组镇痛效果与对照组比较，差异有统计学意义（Plt;0.05）。 结论 痔瘘术后应用针刺法止痛效果好，有良好的临床应用前景。【Abstract】 Objective To determine the effect of acupuncture on the treatment of pain after hemorrhoids and fistula operation. Methods Ninety-three participants who suffered from moderate pain after hemorrhoids and fistula operation in the West China Hospital of Sichuan University from January to June 2008 were enrolled prospectively and randomly assigned into treatment group (n=49) and control group (n=44). The treatment group was treated with acupuncture for postoperative pain relief, whilst Mobic was given orally to the control group. Relief degrees of pain in both groups were observed. Results Efficient power of pain relief was significantly higher in the treatment group compared with the control group (91.83% vs. 68.18%,Plt;0.05). Conclusion Application procedure of acupuncture can significantly relieve postoperative pain after hemorrhoids and fistula operation, which has a good prospect in clinical application.
目的 探讨后路手术中360°植骨融合术治疗腰椎滑脱症的近期疗效。 方法 2008年1月－2011年2月收治39例腰椎滑脱症患者，男21例，女18例；年龄35～75岁，平均51岁。病程12～50个月，平均31个月。滑脱部位：腰3 1例，腰4 11例，腰5 24例，腰4、5 3例。腰椎退变性滑脱27例，峡部裂性滑脱12例。按Meyerding分度：Ⅰ度21例，Ⅱ度13例，Ⅲ度5例。患者均有腰腿痛症状，保守治疗无效后行后路减压、复位及椎弓根钉棒系统内固定，术中以360°行椎间及后外侧三维立体植骨融合，在椎体前中柱采用植骨加椎间融合器的融合方式。术后定期随访，摄X线片检测融合情况，使用视觉模拟疼痛（VAS）评分评估症状缓解情况，Greenough-Fraser综合评分评价腰腿痛治疗结果。 结果 有36例患者获随访，随访时间12～36个月，平均24个月。植骨愈合率100%，愈合时间10～18个月，平均14个月。无内固定松动、断裂、外露及脱落等并发症发生。术前下肢神经根痛VAS评分为（7.52 ± 1.23）分，末次随访时为（1.67 ± 1.18）分；下腰痛术前（6.83 ± 1.51）分，末次随访时为（1.11 ±0.76）分；手术前后比较差异均有统计学意义（P＜0.05）。Greenough-Fraser综合评分术前为（24 ± 7）分，末次随访时为（55 ± 4）分，差异有统计学意义（P＜0.05）。 结论 360°植骨融合术治疗腰椎滑脱症是一种确实有效的融合方法，利于提高相应区域的植骨融合率及恢复椎间隙高度，使融合更稳定。
Objective To compare the outcomes of ranibizumab and conbercept adjunct for pars plana vitrectomy (PPV) in the treatment of proliferative diabetic retinopathy (PDR). MethodsA prospective randomized case-control study. From June 2022 to December 2023, 90 cases (90 eyes) of PDR patients diagnosed through ophthalmic examination at Department of Ophthalmology of Gansu Provincial Hospital were included in the study. All patients underwent the best corrected visual acuity (BCVA), intraocular pressure, B-mode ultrasound, and optical coherence tomography (OCT) examinations. The central macular thickness (CMT) was measured using an OCT instrument. The patients were randomly divided into a intravitreal injection of ranibizumab group (monoclonal-antibody group) and a intravitreal injection of conbercept group (fusion-protein group) using a random number table method, with 45 cases (45 eyes) in each group. Two groups of patients were intravitreal injected with 10 mg/ml ranibizumab or conbercept 0.05 ml, respectively. A standard 23G PPV was performed through the flat part of the ciliary body 3-7 days after intravitreal injection. Relevant examinations were performed using the same equipments and methods as before surgery at postoperative 1 week, 1, 3, 6, and 12 months. The PPV time, intraoperative use of intraocular electrocoagulation, incidence of iatrogenic retinal breaks, and sterile air or silicone oil tamponade rate in the vitreous cavity, the postoperative changes of BCVA and CMT, and incidence of complications were compared between two groups. Independent sample t test was used for inter group comparison. ResultsThe intraoperative utilization rate of intraocular electrocoagulation in the monoclonal-antibody group was higher than that in the fusion-protein group, and the difference was statistically significant (χ2=3.876, P＜0.05). There were no statistically significant differences in the PPV time (t=0.152), intraoperative bleeding rate (χ2=0.800), incidence of iatrogenic retinal breaks (χ2=1.975), and sterile air and silicone oil tamponade rate in the vitreous cavity (χ2=1.607, 1.553) between the two groups (P＞0.05). There were no statistically significant differences in early and late postoperative vitreous hemorrhage (χ2=1.235, 2.355), and re-PPV (χ2=2.355) between two groups (P＞0.05). The BCVA of the fusion-protein group was significantly better than that of the monoclonal-antibody group at postoperative 3 months, and the difference was statistically significant (t=2.428, P＜0.05). The CMT of the fusion-protein group was lower than that in the monoclonal-antibody group at postoperative 1 week, and the difference was statistically significant (t=2.739, P＜0.05). None of the patients experienced endophthalmitis, retinal artery occlusion, or severe cardiovascular events after surgery. ConclusionCompared with intravitreal injection of ranibizumab before PPV, intravitreal injection of conbercept before PPV in PDR patients can shorten the surgical time, reduce intraoperative bleeding rate, lower the rate of electrocoagulation and intraocular tamponade, and incidence of iatrogenic retinal breaks, and improve the visual acuity.